doi:10.1073/pnas.0230620100 Ohnuma K, Uchiyama M, Yamochi T, et al
However, because it can influence weight and hormone balance, any potential effects on menstrual cycles or ovulation should be discussed with your healthcare provider before starting treatment
Hsieh, PhD, a partner and biotechnology analyst with William Blair, and a colleague were similarly positive in a research note: Orforglipron outperformed investor expectations in patients living with both overweight/obesity and type 2 diabetes, which we view as the higher-risk and more difficult-to-treat population. Mini-surge Investors agreed with those upbeat assessments, touching off a mini-surge that sent Lilly shares rising 6% Tuesday, from $695.33 to $736.03
GLP-1 therapies are approved for adults with type 2 diabetes and are not used in type 1 diabetes
In Irvine and Orange County, many patients are looking for a plan that is both effective and sustainable
Blue-purple crystal powder appearance